Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sargramostim Immunogenicity in AML Induction
NCT02520102Phase 2Withdrawn
- Sponsor
- Sanofi
- Start
- Feb 2017
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of sargramostim in acute myeloid leukemia (AML), sponsored by Sanofi. Planned start Feb 2017; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02520102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520102.